Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in solid tumor, sponsored by Hengrui Therapeutics. Started May 2024; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06417554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417554.